Відмінності між версіями «Le disease in peripheral blood or bone marrow even when»
м |
м |
||
| Рядок 1: | Рядок 1: | ||
| − | These | + | These patients are thought of to have accomplished a minimal residual disease (MRD) unfavorable status.17-20 A number of phase II trials have demonstrated that individuals attaining MRD negativity have a signif-icantly longer survival than those that remain MRD good, and that is correct for individuals treated with standard chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Furthermore, a phase III trial performed by the German CLL Study Group (GCLLSG) recently revealed that individuals acquiring MRD negativity had [https://www.medchemexpress.com/radezolid.html RX-1741 web] considerably longer progression-free and overall survivals, irrespectively of your remedy received.18 However, however, a few of these research were flawed by inappropriate statistical analysis, specifically the measurement of time-to-event outcomes from remedy initiation.27 Furthermore, there are lots of caveats to the use of MRD evaluation in individuals with CLL.28 Initially, CLL remains incurable and at the very least 30 of individuals who achieve MRD negativity just after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC ultimately experience a illness relapse within 5 years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic advantage of re-treatment upon [https://www.medchemexpress.com/RA190.html RA190] documentation of MRD positivity following an initial MRD-negative response in comparison to remedy at the time of clinical relapse. The truth is, extremely handful of studies have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and some of the tactics tested, even though efficient, resulted in considerable toxicity.33-35 Thirdly, it might be argued that MRD assessment is just a surrogate for evalution of other adverse prognostic markers considering that, as an example, sufferers with a 17p014 Ferrata Storti Foundation. This is an open-access paper. doi:ten.3324/haematol.2013.099796 The on the web version of this short article has a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(five)R. Santacruz et al.deletion have a larger probability of remaining MRD-positive following therapy in comparison to sufferers without the need of this chromosome abnormality.18 For all these motives, present guidelines for the management of patients with CLL suggest MRD assessment only within clinical trials with "curative intention".36 With all this facts in thoughts, we retrospectively evaluated the impact of MRD around the outcome of patients with CLL getting any front-line therapy in the context of a really detailed prognostic evaluation, such as recently described recurrent gene mutations.survival and general survival were calculated working with a landmark evaluation. All calculations had been performed utilizing either SPSS, version 18.0, or R, version three.0.1. Two-sided P values 0.05 had been regarded as statistically substantial. A detailed explanation with the statistical strategies is obtainable in the On line Supplement.Outcomes Baseline characteristicsThe median age with the entire cohort was 58 years (range, 27-93 years), plus the percentage of patients older than 70 years was 22 . According to D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when pretty sensitive immunophenotypic or molecular methods are used to look for residual disease. |
Версія за 16:13, 11 січня 2018
These patients are thought of to have accomplished a minimal residual disease (MRD) unfavorable status.17-20 A number of phase II trials have demonstrated that individuals attaining MRD negativity have a signif-icantly longer survival than those that remain MRD good, and that is correct for individuals treated with standard chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Furthermore, a phase III trial performed by the German CLL Study Group (GCLLSG) recently revealed that individuals acquiring MRD negativity had RX-1741 web considerably longer progression-free and overall survivals, irrespectively of your remedy received.18 However, however, a few of these research were flawed by inappropriate statistical analysis, specifically the measurement of time-to-event outcomes from remedy initiation.27 Furthermore, there are lots of caveats to the use of MRD evaluation in individuals with CLL.28 Initially, CLL remains incurable and at the very least 30 of individuals who achieve MRD negativity just after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC ultimately experience a illness relapse within 5 years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic advantage of re-treatment upon RA190 documentation of MRD positivity following an initial MRD-negative response in comparison to remedy at the time of clinical relapse. The truth is, extremely handful of studies have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and some of the tactics tested, even though efficient, resulted in considerable toxicity.33-35 Thirdly, it might be argued that MRD assessment is just a surrogate for evalution of other adverse prognostic markers considering that, as an example, sufferers with a 17p014 Ferrata Storti Foundation. This is an open-access paper. doi:ten.3324/haematol.2013.099796 The on the web version of this short article has a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(five)R. Santacruz et al.deletion have a larger probability of remaining MRD-positive following therapy in comparison to sufferers without the need of this chromosome abnormality.18 For all these motives, present guidelines for the management of patients with CLL suggest MRD assessment only within clinical trials with "curative intention".36 With all this facts in thoughts, we retrospectively evaluated the impact of MRD around the outcome of patients with CLL getting any front-line therapy in the context of a really detailed prognostic evaluation, such as recently described recurrent gene mutations.survival and general survival were calculated working with a landmark evaluation. All calculations had been performed utilizing either SPSS, version 18.0, or R, version three.0.1. Two-sided P values 0.05 had been regarded as statistically substantial. A detailed explanation with the statistical strategies is obtainable in the On line Supplement.Outcomes Baseline characteristicsThe median age with the entire cohort was 58 years (range, 27-93 years), plus the percentage of patients older than 70 years was 22 . According to D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when pretty sensitive immunophenotypic or molecular methods are used to look for residual disease.
